WallStSmart

Ciena Corp (CIEN)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 824% more annual revenue ($47.35B vs $5.12B). SNY leads profitability with a 16.0% profit margin vs 4.5%. CIEN appears more attractively valued with a PEG of 2.27. CIEN earns a higher WallStSmart Score of 52/100 (C-).

CIEN

Buy

52

out of 100

Grade: C-

Growth: 8.7Profit: 5.5Value: 3.7Quality: 6.5
Piotroski: 6/9Altman Z: 1.18

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CIEN.

SNYUndervalued (+24.9%)

Margin of Safety

+24.9%

Fair Value

$62.64

Current Price

$43.31

$19.33 discount

UndervaluedFair: $62.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CIEN3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

EPS GrowthGrowth
232.3%10/10

Earnings expanding 232.3% YoY

Market CapQuality
$76.18B9/10

Large-cap with strong market position

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

CIEN4 concerns · Avg: 2.8/10
PEG RatioValuation
2.274/10

Expensive relative to growth rate

Profit MarginProfitability
4.5%3/10

4.5% margin — thin

P/E RatioValuation
345.4x2/10

Premium valuation, high expectations priced in

Price/BookValuation
27.8x2/10

Trading at 27.8x book value

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : CIEN

The strongest argument for CIEN centers on Revenue Growth, EPS Growth, Market Cap. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : CIEN

The primary concerns for CIEN are PEG Ratio, Profit Margin, P/E Ratio. A P/E of 345.4x leaves little room for execution misses. Thin 4.5% margins leave little buffer for downturns.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CIEN profiles as a hypergrowth stock while SNY is a mature play — different risk/reward profiles.

CIEN carries more volatility with a beta of 1.25 — expect wider price swings.

CIEN is growing revenue faster at 33.1% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

CIEN scores higher overall (52/100 vs 51/100) and 33.1% revenue growth. SNY offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ciena Corp

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Ciena Corporation provides hardware, software, and network services that support the transport, routing, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks worldwide. The company is headquartered in Hanover, Maryland.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?